FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial. PMID 41902639 · Epilepsia · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical Trial. PMID 41895581 · Chest · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox-Gastaut syndrome. PMID 41891667 · Epilepsia · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Advanced extrahepatic cholangiocarcinoma and gallbladder cancer: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials. PMID 41887529 · JHEP Rep · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study. PMID 41880832 · Eur Neuropsychopharmacol · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. PMID 41865857 · Am J Med · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Re: Hiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. 2026;89:437-445. PMID 41864760 · Eur Urol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trial. PMID 41864214 · Lancet Infect Dis · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in Neovascular Age-Related Macular Degeneration in Subgroups Defined by Baseline Characteristics. PMID 41861959 · Ophthalmol Retina · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide. PMID 41858082 · J Pediatr Gastroenterol Nutr · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial. PMID 41857682 · Eur J Haematol · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Topical honey as adjunctive therapy to standard dressing in deep neck abscess: a single-blind randomized controlled trial. PMID 41841442 · Acta Otolaryngol · 2026-Jul The study is a randomized controlled trial in humans with original results, but it is excluded because it is not an oncology study, does not involve a drug intervention, is not a Phase III/definitive trial, and does not have a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Value of NBI in the Detection of Local Recurrences of Head and Neck Squamous Cell Carcinoma After (Chemo)radiotherapy: A Randomised Controlled Trial. PMID 41821153 · Clin Otolaryngol · 2026-Jul The study is a randomized controlled trial in oncology (HNSCC) with survival endpoints, but it does not involve a drug-containing intervention. The intervention is diagnostic (NBI vs. WLI endoscopy), not a therapeutic drug. Therefore, it fails the required drug-intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care. PMID 41819988 · Eur J Haematol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Physical rehabilitation for older patients with acute HFpEF (REHAB-HFpEF) trial: Design and rationale. PMID 41812966 · Am Heart J · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Results of a Randomized Phase 2 Trial of One Versus Two 8 Gy Fractions for Painful Bone Metastases. PMID 41812711 · J Pain Symptom Manage · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Minimal Important Difference in N-Terminal Pro-Brain Natriuretic Peptide in Pulmonary Hypertension. PMID 41802593 · Chest · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial. PMID 41801367 · Eur J Nucl Med Mol Imaging · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Win Ratio Analysis to Clarify Clinical Benefits: A Post Hoc Analysis of Phase 3 BOREAS and NOTUS (Two Pivotal Studies to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-Severe COPD With Type 2 Inflammation). PMID 41794122 · Chest · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of Oral Sebetralstat on Anxiety Associated With Hereditary Angioedema Attacks. PMID 41786301 · Clin Exp Allergy · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial. PMID 41786248 · Ann Oncol · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema. PMID 41775339 · Contact Dermatitis · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II). PMID 41763980 · Int J Gynecol Cancer · 2026-Jul Protocol for a Phase III randomized trial in human oncology (ovarian cancer) but lacks a drug-containing intervention (evaluates surgical technique), is not yet reporting results, and does not have a time-to-event primary endpoint (evaluates diagnostic accuracy). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. PMID 41763226 · Lancet HIV · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. PMID 41748387 · Eur Urol · 2026-Jul Eligibility cannot be determined because the record lacks explicit time-to-event endpoint signals and sufficient information about the original formal results and human subject status. Set is_eligible to null. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Adjuvant PD-1 Inhibitors After Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Phase 3 Trials. PMID 41665515 · Urol Pract · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Identifying clinical correlates of drinking clusters during treatment for alcohol use disorder. PMID 41601244 · Am J Addict · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Elenagen, a p62/SQSTM1-encoding plasmid, improves overall survival in patients with platinum-resistant ovarian cancer: a phase II trial. PMID 41577503 · Int J Gynecol Cancer · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Ethics of Clinical Research on Diseases of the Fetus and Newborn: Balancing Benefit-Risk, Autonomy, and Maternal-Fetal Interests. PMID 41468898 · Am J Perinatol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia. PMID 41461173 · Am J Perinatol · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors. PMID 41450180 · Ann Pharmacother · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis. PMID 41405008 · J Eur Acad Dermatol Venereol · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria. PMID 41358486 · Allergy · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia. PMID 41290206 · Am J Perinatol · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Denifanstat for moderate-to-severe acne: A Phase 2, randomized, double-blind, placebo-controlled trial. PMID 41186280 · J Eur Acad Dermatol Venereol · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Intravenous Meloxicam Versus Ketorolac for Pain Control Following Total Joint Arthroplasty: A Double-Blind Randomized Controlled Trial. PMID 41167538 · J Arthroplasty · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of a Volunteer-Led Precision-Medicine Multilevel Intervention on Patient-Reported Outcomes, Receipt of Biomarker Testing, and Time to Treatment: A Randomized Clinical Trial. PMID 40953357 · JCO Oncol Pract · 2026-Jul The study is a randomized trial in oncology (non-small cell lung cancer) with human participants, but it does not meet key eligibility criteria: 1) The intervention is non-drug (volunteer-led education/alert system). 2) The primary/secondary outcomes are patient-reported outcomes (knowledge, activation, satisfaction), a process measure (molecular testing rate), and time to treatment, none of which are time-to-event efficacy endpoints like OS, PFS, DFS, etc. 3) The trial phase is not specified as Phase II/III or Phase III/IIIb in the provided metadata, and cannot be inferred. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| How Sticky Are Clinical Trial Interventions? Site-Level Clinical Trial Participation and Differential Post-Trial Use of a Genomic Test. PMID 40934443 · JCO Oncol Pract · 2026-Jul The record describes an implementation study analyzing the effect of trial participation on post-trial use of a genomic classifier in prostate cancer. It is not a drug-intervention trial, does not report a primary time-to-event efficacy endpoint (like OS/PFS), and does not meet the Phase III requirement. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled Trial. PMID 40854168 · JCO Oncol Pract · 2026-Jul The trial is a randomized controlled trial in oncology patients and reports original results including an OS endpoint. However, it is ineligible because the intervention is non-drug (eHealth platform) and the primary endpoint is quality-of-life, not the time-to-event endpoint required. The phase is also not explicitly confirmed as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation. PMID 41962084 · Swiss Med Wkly · 2026-Jan-31 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The evolving role of neoadjuvant immunotherapy in resectable non-small cell lung cancer: a narrative review. PMID 41660484 · J Thorac Dis · 2026-Jan-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of pleural lavage fluid volume on perioperative outcomes in non-small cell lung cancer patients undergoing video-assisted thoracoscopic lobectomy: a randomized controlled trial. PMID 41659268 · Transl Lung Cancer Res · 2026-Jan-31 The study is a randomized controlled trial in non-small cell lung cancer, but it evaluates a procedural intervention (pleural lavage volume) with no drug intervention. The primary and secondary outcomes (fever rates, complications, hospital stay) are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS, RFS, TTP) and do not involve Kaplan-Meier analysis or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Testing the effects of segmented crowdsource-selected messages to improve intentions to follow colorectal cancer screening recommendations: study protocol for a randomized controlled trial. PMID 41620698 · BMC Public Health · 2026-Jan-31 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Multimodal Prehabilitation In Pancreatic cancer Patients undergoing surgery (PIPS): study protocol for a randomized controlled trial. PMID 41618415 · Trials · 2026-Jan-31 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Combined Intraperitoneal and Systemic Chemotherapy for Peritoneal Metastases: Drug Delivery Concepts, Pharmacokinetics, and Clinical Applications: A Narrative Review. PMID 41754921 · Pharmaceutics · 2026-Jan-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study. PMID 41746067 · Vaccines (Basel) · 2026-Jan-30 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Construction and application of an ERAS-based nursing pathway for postoperative pain management in brain tumor patients. PMID 41618043 · J Neurooncol · 2026-Jan-30 The study is a randomized trial in oncology (brain tumor surgery) with human subjects and reports original results, but it does not meet key eligibility criteria. It is not a Phase III/IIIb or definitive Phase II/III trial (phase is not specified). The intervention is a non-drug nursing pathway (ERAS-based), not a drug-containing intervention. The primary endpoints are pain scores, analgesic consumption, recovery metrics, and satisfaction; none are time-to-event efficacy endpoints like OS, PFS, DFS, EFS, RFS, or TTP, and there is no mention of Kaplan-Meier analysis or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. PMID 41617393 · J Immunother Cancer · 2026-Jan-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial. PMID 41617358 · RMD Open · 2026-Jan-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of Mobilization Facilitated by Wearable Device Enhanced Patient Monitoring/Electrophysiology Pod-Based Feedback on Postoperative Complications Following Colorectal Cancer Surgery: Randomized Controlled Trial. PMID 41616372 · JMIR Mhealth Uhealth · 2026-Jan-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |